We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · December 17, 2019

Upadacitinib in Adults With Moderate to Severe Atopic Dermatitis

Journal of Allergy and Clinical Immunology

 

Additional Info

Journal of Allergy and Clinical Immunology
Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
J. Allergy Clin. Immunol 2019 Nov 28;[EPub Ahead of Print], E Guttman-Yassky, D Thaçi, AL Pangan, HC Hong, KA Papp, K Reich, LA Beck, MF Mohamed, AA Othman, JK Anderson, Y Gu, HD Teixeira, JI Silverberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading